Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Modified Release Anatabine Citrate Formulations
NCT02432313Phase 1Completed
- Sponsor
- Rock Creek Pharmaceuticals
- Start
- Jan 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of anatabine in chronic inflammatory disease and autoimmune diseases (3 arms), sponsored by Rock Creek Pharmaceuticals. Primary endpoint: Pharmacokinetic measures of blood anatabine at 48 hours. Started Jan 2015; status: completed.
02
Drugs
anatabine
03
Conditions
chronic inflammatory diseaseautoimmune diseases
Beyond the preview
Go deeper on NCT02432313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02432313.